Form 8-K - Current report:
SEC Accession No. 0001396814-25-000093
Filing Date
2025-07-10
Accepted
2025-07-10 07:35:28
Documents
13
Period of Report
2025-07-09
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K pcrx-20250709.htm   iXBRL 8-K 34655
2 EX-99.1 sccrifsummer2025-ex991.htm EX-99.1 5932
  Complete submission text file 0001396814-25-000093.txt   161975

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT pcrx-20250709.xsd EX-101.SCH 1792
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT pcrx-20250709_lab.xml EX-101.LAB 21880
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT pcrx-20250709_pre.xml EX-101.PRE 12518
16 EXTRACTED XBRL INSTANCE DOCUMENT pcrx-20250709_htm.xml XML 2831
Mailing Address 2000 SIERRA POINT PARKWAY SUITE 900 BRISBANE CA 94005
Business Address 2000 SIERRA POINT PARKWAY SUITE 900 BRISBANE CA 94005 650-242-8052
Pacira BioSciences, Inc. (Filer) CIK: 0001396814 (see all company filings)

EIN.: 510619477 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35060 | Film No.: 251114832
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)